Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Skybiotech Healthcare (BOM:512036) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Skybiotech Healthcare Net Margin % Related Terms
Skybiotech Healthcare Net Margin % Historical Data
* Premium members only.
The historical data trend for Skybiotech Healthcare's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Conglomerates subindustry, Skybiotech Healthcare's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Skybiotech Healthcare Net Margin % vs Conglomerates Industry
For the Conglomerates industry and Industrials sector, Skybiotech Healthcare's Net Margin % distribution charts can be found below:
* The bar in red indicates where Skybiotech Healthcare's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Skybiotech Healthcare (BOM:512036) has a Net Margin % of -16.60% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Skybiotech Healthcare and its competitors. According to the industry distribution chart, Skybiotech Healthcare ranks #483 out of 542 companies in the Conglomerates industry, placing it in the top 89.1%.
Is Skybiotech Healthcare's Net Margin % too high?
Skybiotech Healthcare's current Net Margin % is -16.60%. Based on the distribution chart, Skybiotech Healthcare ranks #483 out of 542 companies in the Conglomerates industry, which is in the bottom quartile relative to peers. Overall, Skybiotech Healthcare has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does Skybiotech Healthcare's Net Margin % compare to MMM and HON?
According to the Conglomerates industry distribution chart, Skybiotech Healthcare ranks #483 out of 542 companies for Net Margin %. This places Skybiotech Healthcare in the lower half of its industry. The industry median Net Margin % is 4.26. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Conglomerates company?
The median Net Margin % among Conglomerates companies is 4.26, based on 542 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Skybiotech Healthcare and its competitors. For the Conglomerates industry, the median Net Margin % is 4.26 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Skybiotech Healthcare's current Net Margin % is -16.60%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Skybiotech Healthcare stock overvalued right now?
Skybiotech Healthcare (BOM:512036) has a current Net Margin % of -16.60%. The current Net Margin % is -16.60%. Skybiotech Healthcare's overall GF Score™ is 23/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Skybiotech Healthcare (BOM:512036), the current Net Margin % is -16.60% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Skybiotech Healthcare Ltd, formerly Kapil Cotex Ltd is engaged in textiles and allied products, including dyeing, printing, spinning, weaving, and manufacturing fabrics from raw cotton. During the year under review, the company has not generated any revenue from its core business activities. Instead, it earned income from consultancy services for foreign clients and from investments in shares, generating capital gains and dividends. The company's current revenue mainly comes from these non-core activities rather than textile manufacturing.
23GF Score
Get the complete analysis for BOM:512036
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:512036 has been successfully added to your 
